Core Viewpoint - The report details the usage of previously raised funds by Fujian Wancheng Biotechnology Group Co., Ltd., highlighting the financial management and adjustments made to investment projects to enhance operational efficiency and market competitiveness [2][12][14]. Fundraising Overview - The company raised a net amount of RMB 228.60 million from its initial public offering (IPO) after deducting issuance costs [2]. - In a subsequent issuance to specific investors, the company raised RMB 200 million, with a net amount of RMB 193.60 million after expenses [3]. Fund Usage and Management - As of June 30, 2025, the company had utilized RMB 162.59 million from the IPO funds and RMB 142.49 million from the specific issuance funds [4][5]. - The company established special accounts for managing the raised funds, ensuring compliance with regulatory requirements and protecting investor interests [9][10]. Project Adjustments - The company changed the investment project from "Annual Production of 21,000 Tons of Shimeji Mushroom" to "Annual Production of 53,000 Tons of Enoki Mushroom," aiming to improve market competitiveness and reduce production costs [12][14]. - The adjusted investment amount for the new project is RMB 100 million, with a total planned investment of RMB 470.57 million [14]. Financial Performance - As of June 30, 2025, the project for producing 53,000 tons of Enoki mushrooms reported a cumulative loss of RMB 51.39 million, indicating challenges in the edible mushroom business due to market conditions [16].
万辰集团: 中审众环会计师事务所关于福建万辰生物科技集团股份有限公司前次募集资金使用情况的鉴证报告